Dysfunction of von-Hippel Lindau factor causes reduced degradation of HIF leading to renal cancer. Hypoxia-inducible factor-prolyl hydroxylase enzyme inhibitors also lessen HIF destruction and could therefore increase renal cancer
| 出版年: | Frontiers in Pharmacology |
|---|---|
| 第一著者: | |
| フォーマット: | 論文 |
| 言語: | 英語 |
| 出版事項: |
Frontiers Media S.A.
2023-06-01
|
| 主題: | |
| オンライン・アクセス: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1170796/full |
